Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Accumulated Expenses (2023 - 2025)

Neurogene (NGNE) has disclosed Accumulated Expenses for 2 consecutive years, with $9.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 9.71% year-over-year to $9.4 million, compared with a TTM value of $9.4 million through Sep 2025, down 9.71%, and an annual FY2024 reading of $9.7 million, changed N/A over the prior year.
  • Accumulated Expenses was $9.4 million for Q3 2025 at Neurogene, up from $9.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $10.4 million in Q3 2024 and bottomed at $6.8 million in Q1 2024.